HepaCAM and p-mTOR closely correlate in bladder transitional cell carcinoma and hepaCAM expression inhibits proliferation via an AMPK/mTOR dependent pathway in human bladder cancer cells

Journal of Urology

Volumn 190, Issue 5, 2013, Pages 1912-1918

  Wang, Qiuju ^a   Luo, Chunli ^a   Wu, Xiaohou ^b   Du, Hongfei ^a   Song, Xuedong ^a   Fan, Yanru ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma, transitional cell; Cell proliferation; HEPACAM protein, human; MTOR protein, human; Urinary bladder

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN D1; HEPATOCYTE CELL ADHESION MOLECULE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CYSTECTOMY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; ONCOGENE C MYC; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE CULTURE; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; WESTERN BLOTTING;

EID: 84888636951     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.05.013     Document Type: Article

References (30)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11.
2. Jemal A, Bray F, Center MM et al: Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
3. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646.
4. Mitra AP and Cote RJ: Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 2009; 4: 251.
5. Chung Moh M, Hoon Lee L and Shen S: Cloning and characterization of hepaCAM, a novel Ig-like cell adhesion molecule suppressed in human hepatocellular carcinoma. J Hepatol 2005; 42: 833.
6. He Y, Wu X, Luo C et al: Functional significance of the hepaCAM gene in bladder cancer. BMC Cancer 2010; 10: 83.
7. Moh MC, Zhang T, Lee LH et al: Expression of hepaCAM is downregulated in cancers and induces senescence-like growth arrest via a p53/p21-dependent pathway in human breast cancer cells. Carcinogenesis 2008; 29: 2298.
8. Pan C, Wu X, Luo C et al: Exon 2 methylation inhibits hepaCAM expression in transitional cell carcinoma of the bladder. Urol Int 2010; 85: 347.
9. Xu B, He Y, Wu X et al: Exploration of the correlations between interferon-gamma in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-gamma mechanism inhibiting BIU-87 proliferation. J Urol 2012; 188: 1346.
10. Zhang QL, Luo CL, Wu XH et al: HepaCAM induces G1 phase arrest and promotes c-Myc degradation in human renal cell carcinoma. J Cell Biochem 2011; 112: 2910.
11. Populo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci 2012; 13: 1886.
12. Dai B, Kong YY, Ye DW et al: Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int 2009; 104: 1009.
13. Roberts PJ and Der CJ: Targeting the Raf-MEKERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291.
14. Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424.
15. Steelman LS, Chappell WH, Abrams SL et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011; 3: 192.
16. Inoki K, Kim J and Guan KL: AMPK and mTOR in cellular energy homeostasis and drug targets. Annu Rev Pharmacol Toxicol 2012; 52: 381.
17. Zheng QY, Jin FS, Yao C et al: Ursolic acidinduced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem Biophys Res Commun 2012; 419: 741.
18. Kim AY, Lee YS, Kim KH et al: Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010; 24: 1441.
19. Liu Z, Li X, Simoneau AR et al: Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of autophagy. Mol Carcinog 2012; 51: 257.
20. Moh MC, Zhang C, Luo C et al: Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells. J Biol Chem 2005; 280: 27366.
21. Nyfeler B, Chen Y, Li X et al: RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS One 2012; 7: e48548.
22. LoRusso PM: Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment. Oncology 2013; 84: 43.
23. Dazert E and Hall MN: mTOR signaling in disease. Curr Opin Cell Biol 2011; 23: 744.
24. Xu CX, Li Y, Yue P et al: The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo. PLoS One 2011; 6: e20899.
25. Sun CH, Chang YH and Pan CC: Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 2011; 58: 1054.
26. Hirashima K, Baba Y, Watanabe M et al: Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2010; 17: 2486.
27. Kimura N, Tokunaga C, Dalal S et al: A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells 2003; 8: 65.
28. Makhlin I, Zhang J, Long CJ et al: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2011; 108: E84.
29. Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278.
30. Petroulakis E, Mamane Y, Le Bacquer O et al: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006; 94: 195.